Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

Table 1 Summary of Tsc2^+/- results from this study and Messina et al., 2007

	Untreated	Rapamycin	Combination rapamycin plus IFN-g	Untreated	CCI-779 (6–8 months)	CCI-779 (10–12 months)
Number of mice (n)	12	24	24	12	12	12
Tumor score per kidney (ave. ± Std. Err.)	15.00 ± 2.01	0.83 ± .018	0.77 ± 0.20	9.95 ± 1.59	6.00 ± 1.01	3.54 ± 0.76
Percent decrease in tumor score per kidney with treatment	-	94.5%	94.9%	-	39.7%	64.4%
Age of kidney tumor analysis	13 months	13 months	13 months	12 months	12 months	12 months
P value (vs. untreated)	-	P < 0.0001	P < 0.0001	-	-	-
P value (vs. rapamycin)	P < 0.0001	na	P = 0.82	P < 0.0001*	P < 0.0001*	P < 0.0001*
Dose of daily rapamycin (5 days/week)	-	8 mg/kg per day	8 mg/kg per day	-	-	-
Ages, daily rapamycin treatment	-	6–7 months and 12–13 months	6–7 months and 12–13 months	-	-	-
Dose of daily IFN-g (5 days/week)	-	-	20,000 IU	-	-	-
Ages, daily IFN-g treatment	-	-	6–7 months and 12–13 months	-	-	-
Dose of maintenance rapamycin (1 dose per week)	-	16 mg/kg per week	16 mg/kg per week	-	-	-
Ages, weekly rapamycin treatment	-	7–12 months	7–12 months	-	-	-
Dose of daily CCI-779 (5 days/week)	-	-	-	-	8 mg/kg per day	8 mg/kg per day
Ages, daily CCI-779 treatment	-	-	-	-	6–8 months	10–12 months
		This study			Messina et al., 2007

* Tumor score from indicated group from Messina et al., 2007 compared with rapamycin group from this study